Peptide directoryBrain, hypothalamus & pituitary

Gamma-lipotropin

The first 56 residues of beta-lipotropin, left when beta-endorphin is cut away.

Where it comes from

Made in
Pituitary and hypothalamic POMC cells
Sent out by
With the other POMC products
Acts on
  • None established

What it does

  • A by-product of POMC processing that holds beta-MSH in its last eighteen residues 3
  • Weak fat-mobilising activity in animals, with no receptor identified for it 2
  • Measurable in human blood, where it rises alongside ACTH in Addison’s disease, Nelson’s syndrome and ectopic ACTH secretion 1

In medicine

  • None; it is measured only in research assays of POMC processing, which have to separate it from beta-lipotropin because the two share its whole sequence 1
  • Its one clinical consequence is indirect, through beta-MSH, which is cut from its tail and carries a variant linked to obesity 3

Beyond the body’s own use

  • No product and no trial: gamma-lipotropin is an intermediate, and interest in it is interest in what comes out of it
  • What is genuinely unknown is whether it does anything itself; its reported lipotropic activity has never been tied to a receptor or confirmed in people 1
  • It is a useful marker of which route a cell took, because the pieces a cell makes depend on the processing enzymes it carries 2

Sources

  1. Bertagna et al., Simultaneous assay of immunoreactive beta-lipotropin, gamma-lipotropin and beta-endorphin in plasma, Journal of Clinical Investigation 1981
  2. Bicknell, The tissue-specific processing of pro-opiomelanocortin, Journal of Neuroendocrinology 2008
  3. Lee et al., A POMC variant implicates beta-MSH in the control of human energy balance, Cell Metabolism 2006

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.